



Published in final edited form as:

*Br J Nutr.* 2016 October ; 116(7): 1175–1187. doi:10.1017/S0007114516002944.

## The human milk oligosaccharide 2'-fucosyllactose attenuates the severity of experimental necrotising enterocolitis by enhancing mesenteric perfusion in the neonatal intestine

Misty Good<sup>1,2</sup>, Chhinder P. Sodhi<sup>3,4</sup>, Yukihiro Yamaguchi<sup>3,4</sup>, Hongpeng Jia<sup>3,4</sup>, Peng Lu<sup>3,4</sup>, William B. Fulton<sup>3,4</sup>, Laura Y. Martin<sup>3,4</sup>, Thomas Prindle Jr<sup>3,4</sup>, Diego F. Nino<sup>3,4</sup>, Qinjie Zhou<sup>3,4</sup>, Congrong Ma<sup>1,2</sup>, John A. Ozolek<sup>5,6</sup>, Rachael H. Buck<sup>7</sup>, Karen C. Goehring<sup>7</sup>, and David J. Hackam<sup>3,4,\*</sup>

<sup>1</sup>Divisions of Newborn Medicine, Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA

<sup>2</sup>Departments of Pediatrics, The University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA

<sup>3</sup>General Pediatric Surgery, Johns Hopkins University and Bloomberg Children's Center, Johns Hopkins Hospital, Baltimore, MD 21287, USA

<sup>4</sup>Department of Surgery, Johns Hopkins University, Baltimore, MD 21287, USA

<sup>5</sup>Pediatric Pathology, Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA

<sup>6</sup>Departments of Pathology, The University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA

<sup>7</sup>Abbott Nutrition, Columbus, OH 43215, USA

### Abstract

Necrotising enterocolitis (NEC) is a common disease in premature infants characterised by intestinal ischaemia and necrosis. The only effective preventative strategy against NEC is the administration of breast milk, although the protective mechanisms remain unknown. We hypothesise that an abundant human milk oligosaccharide (HMO) in breast milk, 2'-fucosyllactose (2'FL), protects against NEC by enhancing intestinal mucosal blood flow, and we sought to determine the mechanisms underlying this protection. Administration of HMO-2'FL protected against NEC in neonatal wild-type mice, resulted in a decrease in pro-inflammatory markers and preserved the small intestinal mucosal architecture. These protective effects occurred via restoration of intestinal perfusion through up-regulation of the vasodilatory molecule endothelial nitric oxide synthase (eNOS), as administration of HMO-2'FL to *eNOS*-deficient mice or to mice that received eNOS inhibitors did not protect against NEC, and by 16S analysis HMO-2'FL affected the microbiota of the neonatal mouse gut, although these changes do not seem to be the primary mechanism of protection. Induction of eNOS by HMO-2'FL was also

\*Corresponding author: D. J. Hackam, fax +1 410 502 5314, dhackam1@jhmi.edu.

Supplementary material

For supplementary material/s referred to in this article, please visit <http://dx.doi.org/doi:10.1017/S0007114516002944>

The authors declare that there are no conflicts of interest.

observed in cultured endothelial cells, providing a link between eNOS and HMO in the endothelium. These data demonstrate that HMO-2'FL protects against NEC in part through maintaining mesenteric perfusion via increased eNOS expression, and suggest that the 2'FL found in human milk may be mediating some of the protective benefits of breast milk in the clinical setting against NEC.

## Keywords

Necrotising enterocolitis; Human milk oligosaccharides; 2'-Fucosyllactose; Endothelial nitric oxide synthase; Breast milk

Necrotising enterocolitis (NEC) is a serious cause of morbidity and mortality in premature infants, and is a major public health concern due to the increasing number of premature infants<sup>(1)</sup>. NEC is characterised by the sudden onset of ischaemia and necrosis in the small intestine typically, but can occur in the colon, affecting up to 12 % of premature infants, and has a mortality overall of up to 40 %<sup>(1-3)</sup>, in part because current treatment options are limited to gut rest, broad-spectrum antibiotics and surgical resection of necrotic bowel<sup>(4)</sup>. NEC is a gastrointestinal disease in its early stages, but quickly becomes a systemic disease, manifest by cardiorespiratory collapse and signs of systemic sepsis<sup>(1)</sup>. Although the precise causes of NEC remain incompletely understood, our current understanding of the disease identifies a critical link between the administration of enteral formula and its development, as demonstrated by the finding that infants who are fed breast milk are largely protected from NEC development<sup>(5-8)</sup>.

In seeking to understand the mechanisms leading to NEC development, we<sup>(9-12)</sup> as well as others<sup>(13)</sup> have identified a critical role of the lipopolysaccharide (LPS) receptor toll-like receptor 4 (TLR4) in its pathogenesis. In a series of studies summarised in this recent review<sup>(14)</sup>, we and others have shown that TLR4 activation in the intestinal epithelium leads to the loss of enterocytes through apoptosis<sup>(12,15,16)</sup>, followed by delayed repair through inhibition of migration and TLR4-mediated loss of intestinal stem cells<sup>(17)</sup>. These factors lead to the translocation of bacteria and LPS into the circulation where endothelial TLR4 activation occurs, resulting in a loss of endothelial nitric oxide synthase (eNOS), which leads to impaired perfusion and the development of experimental NEC<sup>(18)</sup>.

Several groups have sought to identify potential components of breast milk that could be responsible for exerting the protection against NEC in premature infants<sup>(12,18-22)</sup>, and many of these studies have shed light on the beneficial activities of human milk oligosaccharides (HMO)<sup>(23-30)</sup>. HMO are complex glycans that are abundant in human breast milk and not present in infant formula<sup>(23)</sup> and have beneficial effects on the intestine. There are various pathways by which HMO exert their protective effects on the gut, including selective consumption by protective gut microbes<sup>(28)</sup>, as well as by binding to and thus preventing the adherence of bacteria to the intestinal epithelium<sup>(31)</sup>. HMO have also been shown to be absorbed into the circulation and excreted into the urine, suggesting that these molecules could also exert systemic effects<sup>(32,33)</sup>, and thus may play a protective role against a disease such as NEC, which has both intestinal and systemic components<sup>(1)</sup>. Importantly, there has

been no mechanism that links the potential benefits of HMO against NEC – a disease with largely systemic manifestations and not reliably linked to a particular microbe.

In the current study, we seek to evaluate the role – if any – of an abundant HMO found in breast milk – namely, 2'-fucosyllactose (HMO-2'FL) – in the protection against experimental NEC. To do so, we now focus on our recent observation that TLR4 plays a critical role in NEC development through its ability to modulate intestinal perfusion via eNOS expression as described above<sup>(18)</sup>. We specifically hypothesise that administration of HMO-2'FL will reduce the incidence and severity of NEC in newborn mice through effects on mesenteric perfusion via eNOS regulation.

## Methods

### Statement of ethics

The described animal experiments in this study were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocols were approved by the University of Pittsburgh's Animal Care and Use Committee (protocol 12040382) and Johns Hopkins University (protocol M014M362).

### Cells, materials, mice and reagents

LPS (*Escherichia coli* 0111:B4 purified by gel filtration chromatography, >99 % pure) was obtained from Sigma-Aldrich. eNOS inhibitors – N<sup>5</sup>-(1-iminoethyl)-L-ornithine dihydrochloride (L-NIO) and diphenyleneiodonium chloride (DPI) – were obtained from Santa Cruz Biotechnology. The following antibodies were obtained: eNOS (Enzo Life Sciences) and platelet endothelial cell adhesion molecule 1 (PECAM-1; BD Biosciences). The fluorescein-labelled *Lycopersicon esculentum* (tomato) lectin (Vector Laboratories) was used as a tracer of intestinal perfusion<sup>(18)</sup>. C57BL/6 and *eNOS*<sup>-/-</sup> (B6.129P2-Nos3tm1Unc/J) mice were obtained from the Jackson Laboratory.

HMO-2'FL was produced through a proprietary fermentation process (Kyowa Hakko Bio Co. Ltd). Purity (95.3 %) was established by high-performance ion chromatography with pulsed amperometric detection using relative peak area comparisons. Endotoxin level (0.375 EU/mg) was estimated by limulus assay (limulus amoebocyte lysate QCL-1000; Lonza).

The cell line HUV-EC-C (HUVEC) (ATCC<sup>®</sup> CRL-1730<sup>™</sup>) was obtained from American Type Culture Collection (ATCC) and maintained in endothelial cell basal medium (Cell Applications, Inc.) with low serum growth supplement (Thermo Fisher) at 37°C with 5 % CO<sub>2</sub>. Where indicated, cells were treated with HMO-2'FL (dose 100 µg/ml) 1 h before LPS administration (dose 1 µg/ml), and the induction of TLR4-mediated pro-inflammatory cytokines and *eNOS* expression were measured by quantitative real-time PCR (qRT-PCR) 6 h after administration of LPS. Immunohistochemistry and immunofluorescence were performed as described by Afrazi *et al.*<sup>(34)</sup> and evaluated using a Nikon AZ-C2<sup>+</sup> confocal microscope (Nikon Instruments). SDS-PAGE and qRT-PCR were performed as described by Good *et al.*<sup>(12)</sup>.

## Induction of necrotising enterocolitis in neonatal mice

All animal experiments were approved by the University of Pittsburgh Animal Care and Use Committee. Experimental NEC was induced in 7–10-d-old mice as previously described<sup>(10,34)</sup>. In brief, we used formula gavage (Similac Advance infant formula (Abbott Nutrition):Esbilac (PetAg) canine milk replacer in a 2:1 ratio at a dose of 50 µl NEC formula/g body weight) five times/d, which was supplemented with enteric bacteria obtained from an infant with severe NEC as described in Good *et al.*<sup>(35)</sup> to simulate the dysbiosis seen in human NEC. As both the infant formula and the puppy milk replacer are commercially available, a brief description of each component of the NEC formula is as follows. Similac Advance contains the following ingredients: water, non-fat milk, lactose, high oleic safflower oil, soya oil, coconut oil, galactooligosaccharides and whey protein concentrate. Less than 0.5 % of *C. cohnii* oil, M. Alpina oil,  $\beta$ -carotene, lutein, lycopene, ascorbic acid, soya lecithin, monoglycerides, potassium citrate, calcium carbonate, potassium chloride, carrageenan, ferrous sulphate, magnesium chloride, choline chloride, choline bitartrate, taurine, m-inositol, calcium phosphate, zinc sulphate, potassium phosphate, D- $\alpha$ -tocopheryl acetate, niacinamide, calcium pantothenate, L-carnitine, vitamin A palmitate, cupric sulphate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulphate, phyloquinone, biotin, sodium selenate, vitamin D<sub>3</sub>, cyanocobalamin, salt, potassium hydroxide and nucleotides (AMP, cytidine 5'-monophosphate, disodium GMP, disodium uridine 5'-monophosphate). Esbilac canine milk replacer contains water, condensed, skimmed milk, soyabean oil, sodium caseinate, cream, calcium caseinate, L-methionine, L-arginine, calcium carbonate, choline chloride, lecithin, magnesium sulphate, potassium chloride, monopotassium phosphate, salt, tricalcium phosphate, carrageenan, dipotassium phosphate, dicalcium phosphate, ascorbic acid, ferrous sulphate, sodium hydroxide, zinc sulphate, vitamin A supplement, vitamin E supplement, niacin supplement, calcium pantothenate, copper sulphate, maltodextrins, thiamine hydrochloride, pyridoxine hydrochloride, riboflavin, manganese sulphate, vitamin D<sub>3</sub> supplement, potassium citrate, potassium iodide, folic acid, vitamin B<sub>12</sub> supplement and biotin.

In addition to the formula used to induce NEC, mice were also subjected to 10 min of hypoxia (5 % O<sub>2</sub>, 95 % N<sub>2</sub>) via a chamber (Billups-Rothenberg) twice a day for 4 d. Where indicated, mice were supplemented with HMO-2'FL (5 mg/ml of formula, 0.25 mg/g body weight, once daily). The eNOS inhibitor DPI was dissolved in water–dimethyl sulfoxide (DMSO) (10:90), and a 25-mm stock was prepared of which 2 µl was added to each ml of NEC formula with each feeding as indicated. A 50-mm stock of L-NIO was made with water and 1 µl was added to each ml of NEC formula with each feeding.

## Necrotising enterocolitis severity assessment

Mouse terminal ileal sections were assessed by histology for the degree of mucosal injury according to our previously published scoring system from 0 (normal) to 3 (severe injury)<sup>(36)</sup>, gross morphology, weight loss and by the expressions of pro-inflammatory cytokines by qRT-PCR.

### Assessment of intestinal perfusion in neonatal mice

In mice in which experimental NEC was induced, intestinal perfusion was assessed as previously described in the study by Yazji *et al.* (18). In brief, neonatal mice were intracardiacally injected with the fluorescently labelled tomato lectin (1 mg/ml, dose 5  $\mu$ l/g body weight) for 5 min before euthanasia and intestinal harvest. Terminal ilea were co-stained with PECAM-1, an endothelial cell marker, and whole mounts were evaluated for PECAM-1 and tomato lectin fluorescent emission via confocal microscopy (Nikon AZ-C2<sup>+</sup> confocal microscope). The quantification of the perfusion (villous perfusion index) was assessed as done previously (18). In brief, the sum total of tomato lectin fluorescence divided by the total volume of the mucosal vasculature is expressed as a percentage.

### Measurement of nitric oxide within the intestine

Nitric oxide was measured within the intestine of mice in the indicated treatment groups using the OxiSelect™ In Vitro Nitric Oxide (Nitrite/Nitrate) Assay Kit (Cell Biolabs, Inc.) according to the manufacturer's instructions.

### 16S ribosomal RNA amplicon sequence analysis

Raw paired-end reads output by the MiSeq platform was merged into consensus fragments by FLASH<sup>(37)</sup> and subsequently filtered for quality (maximum error rate 1 %) and length (minimum 200 bp) using Trimmomatic<sup>(38)</sup> and Quantitative Insights into Microbial Ecology (QIIME)<sup>(39,40)</sup>. Spurious hits to the PhiX control genome were identified using Nucleotide Basic Local Alignment Search Tool (BLASTN) and removed. Passing sequences were trimmed of primers, evaluated for chimeras with UCLUST (*de novo* mode)<sup>(41)</sup> and screened for mouse-associated contaminants using Bowtie2<sup>(42)</sup> followed by a more sensitive BLASTN search against the GreenGenes 16S database<sup>(43)</sup>. Chloroplast and mitochondrial contaminants were detected and filtered using the Ribosomal Database Project classifier<sup>(44)</sup> with a confidence threshold of 80 %. High-quality 16S sequences were assigned to operational taxonomic units (OTU) with a taxonomic lineage using Resphera Insight. To remove common bacterial contaminant species associated with DNA extraction kits, we first identified two well-known contaminant species present in all samples (*Variovorax paradoxus* and *Janthinobacterium lividum*) and computed Pearson's  $\rho$  coefficient between these two species and all other OTU. Those OTU with Pearson's  $\rho > 0.2$  for both species were removed. We further removed low-abundance contaminants on the basis of taxa identified by Salter *et al.*<sup>(45)</sup>. To normalise across samples, 16S profiles were subsampled to 1124 sequences per sample before downstream statistical comparisons. Differentially abundant taxa were detected using the negative binomial test with *P*-value correction using the false discovery rate<sup>(46,47)</sup>.  $\beta$ -Diversity calculations and principal coordinate analysis (PCoA) was performed using QIIME<sup>(39,40)</sup>. Differences in  $\beta$ -diversity were evaluated using the Mann–Whitney *U* test.

### Statistical analysis

In our experimental NEC experiments, each mouse represents an individual symbol on a graph. Because of different numbers of pups randomised to each group, the numbers may vary between data sets, but each is shown in the relevant data set, and statistical analysis was

performed using ANOVA for multiple groups or Student's *t* test for paired groups using PRISM version 6.0 (GraphPad). Statistical significance was accepted at  $P < 0.05$ .

### Quantitative real-time PCR

Quantitative real-time PCR was performed as previously described using the Bio-Rad CFX96 Real-Time System (Bio-Rad)<sup>(36)</sup> using the primers listed in Table 1 relative to the housekeeping gene ribosomal protein large, P0 (*RPL0*).

## Results

### Necrotising enterocolitis severity in mice is reduced by the addition of the human milk oligosaccharide 2'-fucosyllactose to the formula

As shown in Fig. 1, animals subjected to this experimental model developed gross evidence of small intestinal ischaemia, pneumatosis intestinalis and inflammation (Fig. 1(a)), as well as histological evidence of mucosal destruction and inflammatory influx (Fig. 1(b)), compared with breast-fed controls. Importantly, the administration of HMO-2'FL (0.25 mg/g body weight once daily during the model) significantly reduced the severity of NEC as compared with mice that were administered standard NEC formula, as was determined by assessment of the degree of gross and microscopic intestinal mucosal injury (Fig. 1(a) and (b)), preservation of daily weights (Fig. 1(c)), mucosal severity score (Fig. 1(d)) and by the expressions of the pro-inflammatory mediators that our laboratory<sup>(9–11,16)</sup> and others<sup>(48)</sup> have shown to be important in NEC, including inducible nitric oxide synthase (*iNOS*), *IL-6*, *IL-1 $\beta$*  and *TLR4* (Fig. 1(e)). Taken together, the supplementation of HMO-2'FL in the formula protects against the development of experimental NEC.

Given the possibility that there could be microbial effects, we next sought to describe the microbiota of the animals treated with HMO-2'FL. As shown in Fig. 2 and 3, taxonomic profiles at the family level reveal several well-represented taxa including Enterobacteriaceae, Lactobacillaceae and Clostridiaceae. We found Enterobacteriaceae to be generally more abundant in the experimental NEC group, whereas Lactobacillaceae appeared to be more abundant in the breast-fed group. Furthermore, differential abundance analysis between the mouse groups confirmed the associations with Enterobacteriaceae and Lactobacillaceae between the breast-fed controls as compared with animals that underwent experimental NEC; however, we did not see an association with HMO treatment (Fig. 2(b)). For Ruminococcaceae and Enterococcaceae, we observed some significant differences between HMO and their respective control groups (Fig. 2(b)). For example, Enterococcaceae was significantly more abundant in the breast-fed control group relative to the HMO-2'FL-treated group (Fig. 2(b)). We next wanted to analyse the microbial community diversity between the different treatment groups.  $\beta$ -Diversity analysis enabled us to compare total community composition among samples to look for broader associations beyond any single taxon. Using the Hellinger distance metric in QIIME, followed by PCoA, we observed a strong association with breast-fed compared with formula-fed (FF) animals (Fig. 3). Moreover, we can compare the  $\beta$ -diversity distances within and between the groups to see whether there are distinctive associations. In this case, we found that for both HMO-fed

groups, the intestinal microbiomes of the mice were significantly more homogeneous than the breast-fed and FF groups (Fig. 3).

**The addition of the human milk oligosaccharide 2'-fucosyllactose prevented the inhibition on mesenteric perfusion observed in experimental necrotising enterocolitis in newborn mice**

In order to define the mechanisms by which HMO-2'FL could protect against the development of NEC, we next turned our attention to the effects of HMO-2'FL on the potential regulation of eNOS-mediated mesenteric blood flow by performing mesenteric micro-angiography in mice that underwent experimental NEC. To do so, we first assessed the degree of mesenteric perfusion in the mouse model of experimental NEC in the presence or absence of HMO-2'FL supplementation to the formula. As shown in Fig. 4, the intestinal perfusion in mice that were FF was significantly reduced compared with breast-fed controls, consistent with our previous findings<sup>(18)</sup>. Importantly, the addition of HMO-2'FL restored perfusion to levels comparable with that of mice that were breast-fed on each day of the model, as observed in Fig. 4(a) and quantified in Fig. 4(b). The improvement in perfusion corresponded to a pink and healthy appearing intestine in breast-fed mice as compared with the dusky bowel seen in NEC, which was reversed in the presence of HMO-2'FL towards a healthy, pink and perfused appearance. Taken together, these findings illustrate that HMO-2'FL restores intestinal perfusion in NEC. We next sought to explore the potential mechanisms involved and focused on the effects of the vasodilatory molecule eNOS.

**Human milk oligosaccharide 2'-fucosyllactose maintains the expression of endothelial nitric oxide synthase in necrotising enterocolitis, and thus restores intestinal perfusion in neonatal mice**

Having now shown that HMO-2'FL restores mesenteric perfusion in NEC, we next sought to investigate the possibility that HMO-2'FL may affect the expression of eNOS. To do so, we assessed the expression of eNOS in the intestine of mice with and without NEC in the presence or absence of HMO-2'FL. As shown in Fig. 4, the expression of *eNOS* in the intestine was significantly reduced in FF mice compared with breast-fed control mice, and this was restored after HMO-2'FL induction (Fig. 4(c) and (d (i, ii))). The finding that HMO-2'FL could restore the expression of *eNOS* in the newborn gut in the setting of NEC raises the intriguing possibility that perhaps the protection against NEC by HMO-2'FL occurs via induction of *eNOS* expression. To assess this directly, we next utilised two approaches to inhibit eNOS – the use of pharmacological inhibitors and the use of *eNOS* knockout mice – and sought to determine whether HMO-2'FL could *still* protect against NEC development under conditions of eNOS inhibition. As shown in Fig. 5, we next treated mice with eNOS inhibitors L-NIO dihydrochloride and DPI. Importantly, under conditions of eNOS inhibition (verification in the online Supplementary Fig. S1(a)), HMO-2'FL failed to protect against NEC as demonstrated by histology, the pro-inflammatory cytokine *IL-1 $\beta$*  and NEC severity score (Fig. 5(a) and (c)), revealing that HMO-2'FL acts in part via eNOS activity. To assess whether eNOS expression was *required* for the protection exerted by HMO-2'FL against NEC, we next performed studies in *eNOS*<sup>-/-</sup> mice (Fig. 6, online Supplementary Fig. S1(b)) and as shown in the study by Shesely *et al.*<sup>(49)</sup>. As shown in Fig. 6, *eNOS*<sup>-/-</sup> mice were significantly vulnerable to experimental NEC, consistent with our

previous studies<sup>(18)</sup>, and administration of HMO-2'FL did not confer protection as demonstrated by a disruption in the intestinal mucosal architecture, increase in pro-inflammatory cytokines and NEC severity, as well as significantly reduced intestinal perfusion (Fig. 6(a) and (d)). Taken together, these findings demonstrate that HMO-2'FL is protective against experimental NEC in a manner that is dependent on the expression and function of eNOS.

### **Lipopolysaccharide decreases the expression of endothelial nitric oxide synthase in HUVEC endothelial cells and this decrease is attenuated by human milk oligosaccharide 2'-fucosyllactose**

In the final series of studies, we sought to explore in greater detail the potential mechanisms by which HMO-2'FL could regulate eNOS expression – and therefore mesenteric perfusion – in the newborn gut. To do so, we first examined whether HMO-2'FL could regulate the mRNA expression of *eNOS* in HUVEC endothelial cells in the presence of either LPS as a TLR4 ligand or LPS in the presence of HMO-2'FL to mimic the situation observed in the mesenteric endothelium. As shown in Fig. 7, TLR4 activation reduced the expression of *eNOS* mRNA in HUVEC (Fig. 7(a)), consistent with our previous findings in primary cultured endothelial cells<sup>(18)</sup>. Importantly, the addition of HMO-2'FL restored *eNOS* expression as demonstrated by immunocytochemistry (Fig. 7(b)), consistent with the intestinal protein expression shown in Fig. 4(d), and demonstrated a clear role of HMO-2'FL in the regulation of *eNOS* gene expression and function.

## **Discussion**

In the current study, we utilised an experimental mouse model of NEC, which recapitulates several of the features seen in premature infants with NEC, including gross evidence of small intestinal ischaemia, pneumatosis intestinalis and inflammation, as well as histological evidence of mucosal destruction<sup>(12,15,16,18)</sup>, to demonstrate that the administration of formula containing an abundant HMO in human milk – namely, 2'FL – significantly reduces the severity of experimental NEC in newborn mice. In seeking to define the mechanisms involved, we and others have shown that TLR4 signalling in the gut leads to NEC via mucosal disruption, leading to LPS translocation and a loss of eNOS, which results in impaired perfusion and the development of intestinal ischaemia<sup>(18,50)</sup>. We have now determined that HMO-2'FL-supplemented formula acts by regulating the degree of blood flow to the newborn intestine via eNOS, and that this novel pathway may explain some of the previously unrecognised benefits of this breast milk oligosaccharide.

The current findings may shed light on the impact of other aspects of maternal breast milk production that could impact on the likelihood of NEC development to occur. Specifically, previous authors have noted that nearly 20 % of women in the population are homozygous for common mutations in the secretor gene fucosyltransferase 2 (*FUT2*) and are unable to produce HMO-2'FL<sup>(51)</sup>, which has been shown to impact the intestinal microbiota of their infants<sup>(52)</sup>. The studies on the relationship of *FUT2* mutations and risk for NEC to date have focused predominantly on the phenotype or genotype of the baby rather than the mother<sup>(51,52)</sup>. We now speculate that any increase in NEC in premature infants receiving

milk from homozygous *FUT2* mutant mothers may reflect a lack of endogenous 2'FL, suggesting that supplementing their milk with 2'FL could benefit their premature infants through NEC protection.

Our findings extend our knowledge on the mechanisms by which HMO act on the neonatal intestine, and provide additional insights into the benefit of breast milk that is observed in premature infants at risk for developing NEC. Specifically, the molecular details underlying the capacity of two genera of gut bacteria to consume HMO have been demonstrated, including *Bifidobacterium*<sup>(53)</sup> and *Bacteroidetes*<sup>(54)</sup>. Indeed, the presence of gram-negative bacteria including *E. coli* and *Klebsiella* has been associated with NEC outbreaks, and are commonly seen in the blood and stool of patients with this disease<sup>(55)</sup>. HMO have also been shown to have structural homology to cell surface glycans, and can therefore act as molecular mimics, or decoys, by binding to luminal bacteria, and thereby prevent binding to the intestinal epithelium<sup>(56)</sup>, thus potentially reducing the degree of bacterial inflammation and activation of toll-like receptors on the intestinal epithelium, which we have shown to be required for NEC development<sup>(10,15,17,34,36,57)</sup>. Moreover, analysis of the microbiota revealed that supplementation of HMO-2'FL to the experimental NEC formula increased the faecal content of Ruminococcaceae, a family of bacteria of class Clostridia, which typically increase in premature infants as they mature and approach 36 weeks of postconceptional age<sup>(58)</sup>. Although HMO-2'FL appears to affect the microbiota, these changes do not seem to be the primary mechanism of protection against NEC. The current findings extend the studies by Goehring *et al.*<sup>(32)</sup> who demonstrated that in addition to these local effects HMO are absorbed systemically in human infants, which in this case explains the effect on mesenteric perfusion through the activity of the vasodilator eNOS. Furthermore, 2'FL has been demonstrated in the plasma of breast-fed infants, although in lesser abundance than several other HMO<sup>(33)</sup>, and in the urine of breast milk-fed premature infants<sup>(59)</sup>. Although our studies did not directly test the systemic absorption of 2'FL, other authors have elegantly shown that HMO are absorbed in the intestine and can be measured in the serum and urine of *rats*, demonstrating the significance of the effects of HMO on other species<sup>(19,60)</sup>. In determining which HMO are present in mouse breast milk, Prieto *et al.*<sup>(61)</sup> have shown that 2'FL is not present in mouse milk, while 3'FL indeed is. Importantly, the biological significance of the differential expression of HMO in breast milk across various species is unknown. It is noteworthy that the current study is supported by previous studies by Jantscher-Krenn *et al.*<sup>(19)</sup> who showed that the addition of the HMO disialyllacto-*N*-tetraose prevents NEC in neonatal rats. Although these studies did not provide a mechanism to explain these protective effects, and indeed the effects may be structure specific, we now speculate that the protection achieved was similar to that observed in the current study, and involved an enhanced mesenteric perfusion. Additional effects on the microbiota and on bacterial enterocyte signalling may also play a role in the protection in these two studies, and additional work will be required to determine these precise effects. It is possible that 2'FL gets absorbed into the circulation, attenuates endothelial TLR4 signalling and subsequently maintains eNOS levels. Moreover, it is likely that breast milk has various direct TLR4 inhibitors, as we have recently identified a class of small molecule inhibitors of TLR4<sup>(62)</sup>, which are themselves oligosaccharides, suggesting that HMO-2'FL itself may inhibit TLR4 signalling. In support of this possibility, the expression of *TLR4* was reduced in the mucosa

of mice after administration of HMO-2'FL. Furthermore, it has recently been reported that HMO-2'FL modulates the expression of cluster of differentiation 14 (CD14), a molecule that is essential for LPS binding and optimal TLR4 signalling<sup>(63)</sup>. The current study thus advances our understanding of the mechanisms by which breast milk may protect against the development of NEC.

In summary, the current findings reveal an important role for HMO-2'FL in the protection against the development of NEC in newborn mice through the maintenance of mesenteric perfusion via a mechanism that requires the expression of eNOS. These findings expand our understanding about the protective benefits of breast milk for premature infants, in which HMO are present in high amounts, and also indicate that in addition to the established roles of HMO on the microbiota or on the epithelial surface, these molecules may have key roles when absorbed systemically. Although our preclinical studies were performed in neonatal mice rather than premature infants, the current studies also suggest that 2'FL is one of the components within human breast milk found to be protective against NEC, which remains an important goal of neonatal nutrition research. Furthermore, these studies reinforce the statements by the American Academy of Pediatrics Section on Breastfeeding and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition that the preferred feeding for premature infants should be the mother's own milk with donor human milk from an established human milk bank as a second choice if the mother's milk supply is inadequate<sup>(64,65)</sup>.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

M. G. is supported by K08DK101608 from the National Institutes of Health and the Children's Hospital of Pittsburgh of the UPMC Health System. D. J. H. is supported by a sponsored research grant from Abbott Nutrition, as well as R01DK083752 and R01GM078238 from the National Institutes of Health.

M. G., C. P. S., R. H. B., K. C. G. and D. J. H. designed and/or performed experiments, analysed results, wrote and edited the manuscript; Y. Y., H. J., P. L., W. B. F., L. Y. M., T. P., D. F. N., Q. Z. and C. M. performed experiments and analysed data.

## Abbreviations

<b>2'FL</b>	2'-fucosyllactose
<b>eNOS</b>	endothelial nitric oxide synthase
<b>HMO</b>	human milk oligosaccharide
<b>LPS</b>	lipopolysaccharide
<b>NEC</b>	necrotising enterocolitis
<b>TLR4</b>	toll-like receptor 4

## References

1. Neu J, Walker WA. Necrotizing enterocolitis. *N Engl J Med*. 2011; 364:255–264. [PubMed: 21247316]
2. Fitzgibbons SC, Ching Y, Yu D, et al. Mortality of necrotizing enterocolitis expressed by birth weight categories. *J Pediatr Surgery*. 2009; 44:1072–1075. discussion 1075–1076.
3. Lin PW, Stoll BJ. Necrotising enterocolitis. *Lancet*. 2006; 368:1271–1283. [PubMed: 17027734]
4. Obladen M. Necrotizing enterocolitis – 150 years of fruitless search for the cause. *Neonatology*. 2009; 96:203–210. [PubMed: 19407465]
5. Sullivan S, Schanler RJ, Kim JH, et al. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. *J Pediatr*. 2010; 156:562–567. e1. [PubMed: 20036378]
6. Lucas A, Cole TJ. Breast milk and neonatal necrotising enterocolitis. *Lancet*. 1990; 336:1519–1523. [PubMed: 1979363]
7. Newburg DS, Walker WA. Protection of the neonate by the innate immune system of developing gut and of human milk. *Pediatr Res*. 2007; 61:2–8. [PubMed: 17211132]
8. Meinen-Derr J, Poindexter B, Wrage L, et al. Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. *J Perinatol*. 2009; 29:57–62. [PubMed: 18716628]
9. Leaphart CL, Cavallo J, Gribar SC, et al. A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. *J Immunol*. 2007; 179:4808–4820. [PubMed: 17878380]
10. Sodhi CP, Neal MD, Siggers R, et al. Intestinal epithelial toll-like receptor 4 regulates goblet cell development and is required for necrotizing enterocolitis in mice. *Gastroenterology*. 2012; 143:708–718. e1–e5. [PubMed: 22796522]
11. Good M, Siggers RH, Sodhi CP, et al. Amniotic fluid inhibits toll-like receptor 4 signaling in the fetal and neonatal intestinal epithelium. *Proc Natl Acad Sci*. 2012; 109:11330–11335. [PubMed: 22733781]
12. Good M, Sodhi CP, Egan CE, et al. Breast milk protects against the development of necrotizing enterocolitis through inhibition of toll-like receptor 4 in the intestinal epithelium via activation of the epidermal growth factor receptor. *Mucosal Immunol*. 2015; 8:1166–1179. [PubMed: 25899687]
13. Jilling T, Simon D, Lu J, et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. *J Immunol*. 2006; 177:3273–3282. [PubMed: 16920968]
14. Nino DF, Sodhi CP, Hackam DJ. Necrotizing enterocolitis: mechanisms and management. *Nat Rev Gastroenterol Hepatol*. 2016 In the press.
15. Afrazi A, Branca MF, Sodhi CP, et al. Toll like receptor 4-mediated endoplasmic reticulum stress in intestinal crypts induces necrotizing enterocolitis. *J Biol Chem*. 2014; 289:9584–9599. [PubMed: 24519940]
16. Egan CE, Sodhi CP, Good M, et al. Toll-like receptor 4-mediated lymphocyte influx induces neonatal necrotizing enterocolitis. *J Clin Invest*. 2015; 126:495–508.
17. Neal MD, Sodhi CP, Jia H, et al. Toll-like receptor 4 is expressed on intestinal stem cells and regulates their proliferation and apoptosis via the p53 up-regulated modulator of apoptosis. *J Biol Chem*. 2012; 287:37296–37308. [PubMed: 22955282]
18. Yazji I, Sodhi CP, Lee EK, et al. Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-nitrite signaling. *Proc Natl Acad Sci U S A*. 2013; 110:9451–9456. [PubMed: 23650378]
19. Jantscher-Krenn E, Zharebtsov M, Nissan C, et al. The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in neonatal rats. *Gut*. 2012; 61:1417–1425. [PubMed: 22138535]
20. Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. *JAMA*. 2009; 302:1421–1428. [PubMed: 19809023]

21. Dvorak B, Halpern MD, Holubec H, et al. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. *Am J Physiol Gastrointest Liver Physiol.* 2002; 282:G156–G164. [PubMed: 11751169]
22. Radulescu A, Zorko NA, Yu X, et al. Preclinical neonatal rat studies of heparin-binding EGF-like growth factor in protection of the intestines from necrotizing enterocolitis. *Pediatr Res.* 2009; 65:437–442. [PubMed: 19127210]
23. Newburg DS. Neonatal protection by an innate immune system of human milk consisting of oligosaccharides and glycans. *J Anim Sci.* 2009; 87:26–34. [PubMed: 19028867]
24. Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. *Annu Rev Nutr.* 2005; 25:37–58. [PubMed: 16011458]
25. Bode L. Human milk oligosaccharides: prebiotics and beyond. *Nutr Rev.* 2009; 67(Suppl. 2):S183–S191. [PubMed: 19906222]
26. Bode L. Human milk oligosaccharides: every baby needs a sugar mama. *Glycobiology.* 2012; 22:1147–1162. [PubMed: 22513036]
27. Bode L, Kunz C, Muhly-Reinholz M, et al. Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by human milk oligosaccharides. *Thromb Haemost.* 2004; 92:1402–1410. [PubMed: 15583750]
28. Wang M, Li M, Wu S, et al. Fecal microbiota composition of breast-fed infants is correlated with human milk oligosaccharides consumed. *J Pediatr Gastroenterol Nutr.* 2015; 60:825–833. [PubMed: 25651488]
29. Zivkovic AM, German JB, Lebrilla CB, et al. Human milk glyco-biome and its impact on the infant gastrointestinal microbiota. *Proc Natl Acad Sci U S A.* 2011; 108(Suppl. 1):4653–4658. [PubMed: 20679197]
30. Marcobal A, Barboza M, Froehlich JW, et al. Consumption of human milk oligosaccharides by gut-related microbes. *J Agric Food Chem.* 2010; 58:5334–5340. [PubMed: 20394371]
31. Ruiz-Palacios GM, Cervantes LE, Ramos P, et al. *Campylobacter jejuni* binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. *J Biol Chem.* 2003; 278:14112–14120. [PubMed: 12562767]
32. Goehring KC, Kennedy AD, Prieto PA, et al. Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants. *PLOS ONE.* 2014; 9:e101692. [PubMed: 24999728]
33. Ruhaak LR, Stroble C, Underwood MA, et al. Detection of milk oligosaccharides in plasma of infants. *Anal Bioanal Chem.* 2014; 406:5775–5784. [PubMed: 25059723]
34. Afrazi A, Sodhi CP, Good M, et al. Intracellular heat shock protein-70 negatively regulates TLR4 signaling in the newborn intestinal epithelium. *J Immunol.* 2012; 188:4543–4557. [PubMed: 22461698]
35. Good M, Sodhi CP, Ozolek JA, et al. *Lactobacillus rhamnosus* HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets: evidence in mice for a role of TLR9. *Am J Physiol Gastrointest Liver Physiol.* 2014; 306:G1021–G1032. [PubMed: 24742987]
36. Anand RJ, Leaphart CL, Mollen KP, et al. The role of the intestinal barrier in the pathogenesis of necrotizing enterocolitis. *Shock.* 2007; 27:124–133. [PubMed: 17224785]
37. Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. *Bioinformatics.* 2011; 27:2957–2963. [PubMed: 21903629]
38. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics.* 2014; 30:2114–2120. [PubMed: 24695404]
39. Kuczynski J, Stombaugh J, Walters WA, et al. Using QIIME to analyze 16S rRNA gene sequences from microbial communities. *Curr Protoc Bioinformatics.* 2011; 36:10.7.1–10.7.20. Chapter 10, Unit 10.17.
40. Caporaso JG, Bittinger K, Bushman FD, et al. PyNAST: a flexible tool for aligning sequences to a template alignment. *Bioinformatics.* 2010; 26:266–267. [PubMed: 19914921]
41. Edgar RC, Haas BJ, Clemente JC, et al. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics.* 2011; 27:2194–2200. [PubMed: 21700674]
42. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nature Methods.* 2012; 9:357–359. [PubMed: 22388286]

43. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *ISME J.* 2012; 6:610–618. [PubMed: 22134646]
44. Wang Q, Garrity GM, Tiedje JM, et al. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol.* 2007; 73:5261–5267. [PubMed: 17586664]
45. Salter SJ, Cox MJ, Turek EM, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. *BMC Biol.* 2014; 12:87. [PubMed: 25387460]
46. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. *Behav Brain Res.* 2001; 125:279–284. [PubMed: 11682119]
47. McMurdie PJ, Holmes S. phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. *PLOS ONE.* 2013; 8:e61217. [PubMed: 23630581]
48. Jain SK, Baggerman EW, Mohankumar K, et al. Amniotic fluid-borne hepatocyte growth factor protects rat pups against experimental necrotizing enterocolitis. *Am J Physiol Gastrointest Liver Physiol.* 2014; 306:G361–G369. [PubMed: 24407592]
49. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. *Proc Natl Acad Sci U S A.* 1996; 93:13176–13181. [PubMed: 8917564]
50. Yu X, Radulescu A, Zorko N, et al. Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis. *Gastroenterology.* 2009; 137:221–230. [PubMed: 19361505]
51. Demmert M, Schaper A, Pagel J, et al. FUT 2 polymorphism and outcome in very-low-birth-weight infants. *Pediatr Res.* 2015; 77:586–590. [PubMed: 25642664]
52. Wacklin P, Makivuokko H, Alakulppi N, et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. *PLoS ONE.* 2011; 6:e20113. [PubMed: 21625510]
53. Garrido D, Barile D, Mills DA. A molecular basis for bifidobacterial enrichment in the infant gastrointestinal tract. *Adv Nutr.* 2012; 3:415S–421. [PubMed: 22585920]
54. Marcobal A, Sonnenburg JL. Human milk oligosaccharide consumption by intestinal microbiota. *Clin Microbiol Infect.* 2012; 18(Suppl. 4):12–15. [PubMed: 22647041]
55. Kosloske AM, Ulrich JA. A bacteriologic basis for the clinical presentations of necrotizing enterocolitis. *J Pediatr Surg.* 1980; 15:558–564. [PubMed: 7411368]
56. Morrow AL, Ruiz-Palacios GM, Jiang X, et al. Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. *J Nutr.* 2005; 135:1304–1307. [PubMed: 15867329]
57. Gribar SC, Sodhi CP, Richardson WM, et al. Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. *J Immunol.* 2009; 182:636–646. [PubMed: 19109197]
58. La Rosa PS, Warner BB, Zhou Y, et al. Patterned progression of bacterial populations in the premature infant gut. *Proc Natl Acad Sci U S A.* 2014; 111:12522–12527. [PubMed: 25114261]
59. Underwood MA, Gaerlan S, De Leoz ML, et al. Human milk oligosaccharides in premature infants: absorption, excretion, and influence on the intestinal microbiota. *Pediatr Res.* 2015; 78:670–677. [PubMed: 26322410]
60. Santos-Fandila A, Zafra-Gomez A, Vazquez E, et al. Ultra high performance liquid chromatography-tandem mass spectrometry method for the determination of soluble milk glycans in rat serum. *Talanta.* 2014; 118:137–146. [PubMed: 24274281]
61. Prieto PA, Mukerji P, Kelder B, et al. Remodeling of mouse milk glycoconjugates by transgenic expression of a human glycosyltransferase. *J Biol Chem.* 1995; 270:29515–29519. [PubMed: 7493992]
62. Neal MD, Jia H, Eyer B, et al. Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors. *PLOS ONE.* 2013; 8:e65779. [PubMed: 23776545]
63. He Y, Liu S, Kling DE, et al. The human milk oligosaccharide 2'-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation. *Gut.* 2016; 65:33–46. [PubMed: 25431457]


64. Eidelman AI, Schanler RJ, Johnston M, et al. Breastfeeding and the use of human milk. *Pediatrics*. 2012; 129:e827–e841. [PubMed: 22371471]
65. Nutrition, ECo; Arslanoglu, S.; Corpeleijn, W., et al. Donor human milk for preterm infants: current evidence and research directions. *J Pediatr Gastroenterol Nutr*. 2013; 57:535–542. [PubMed: 24084373]

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript

**Fig. 1.**


The addition of the human milk oligosaccharide (HMO) 2'-fucosyllactose to infant formula attenuates necrotising enterocolitis (NEC) severity in newborn mice. (a) Representative gross images of the intestine from wild-type neonatal mice that were either breast-fed (BF) or induced to develop NEC in the absence or presence of HMO in their feeds. (b) Representative haematoxylin–eosin micrographs of the terminal ileum of wild-type mice that were either BF, breast-fed with daily administration of HMO (BF + HMO) or received NEC formula with or without the addition of HMO to their feeds (FF or FF + HMO). (c)

Daily body weights (g) of experimental animals for the duration of the NEC model.  BF;  FF;  BF + HMO;  FF + HMO. (d) NEC severity score (0–3) assigned by a pathologist blinded to the study conditions and treatment groups. (e) The ratio of the measured mRNA expression of the pro-inflammatory genes within the intestine including inducible nitric oxide synthase (*iNOS*), *IL-6*, *IL-1β* and toll-like receptor 4 (*TLR4*) of the indicated groups relative to the housekeeping gene *RPL0*, as in the study by Good *et al.*<sup>(12)</sup>. \*  $P < 0.05$  *v.* BF control animals, \*\*  $P < 0.05$  *v.* FF. Values are means with their standard errors. Scale bar is 50 μm. Representative of three separate experiments, where each mouse represents an individual symbol on a graph. qRT-PCR, quantitative real-time PCR.




**Fig. 2.** Characterisation of the microbiota in mice treated with the human milk oligosaccharide (HMO) 2'-fucosyllactose (2'FL). (a) Taxonomic profiles at the family level for the microbiotas of pups treated with HMO-2'FL with necrotising enterocolitis (NEC) or breast-fed controls. █, Other taxa; █, Proteobacteria\_Alphaproteobacteria\_Sphingomonadales\_Sphingomonadaceae; █, Proteobacteria\_Gammaproteobacteria\_Pseudomonadales\_Moraxellaceae; █, Proteobacteria\_Gammaproteobacteria\_Pseudomonadales\_Pseudomonadaceae; █, Firmicutes\_Bacilli\_Bacillales\_Staphylococcaceae; █, Proteobacteria\_Gammaproteobacteria\_Pasteurellales\_Pasteurellaceae; █, Firmicutes\_Clostridia\_Clostridiales\_Incertae sedis;

Firmicutes\_Clostridia\_Clostridiales\_Ruminococcaceae; ■,  
Firmicutes\_Bacilli\_Lactobacillales\_Enterococcaceae; ■,  
Firmicutes\_Bacilli\_Lactobacillales\_Streptococcaceae; ■,  
Firmicutes\_Clostridia\_Clostridiales\_Clostridiaceae 1; ■,  
Firmicutes\_Bacilli\_Lactobacillales\_Lactobacillaceae; ■,  
Proteobacteria\_Gammaproteobacteria\_Enterobacteriales\_Enterobacteriaceae. (b)  
Differential abundance analysis of the indicated treatment groups. ■, Enterobacteriaceae; ■,  
Lactobacillaceae; ■, Ruminococcaceae; ■, Enterococcaceae. BF, breast-fed; CNTRL,  
control; FF, formula fed. \* Adjusted  $P < 0.05$ ; \*\* adjusted  $P < 0.01$ ; \*\*\* adjusted  $P < 0.001$ .




**Fig. 3.**  $\beta$ -Diversity analysis of the microbiota in mice treated with the human milk oligosaccharide (HMO) 2'-fucosyllactose. (a, b)  $\beta$ -Diversity analysis of the microbiota of the indicated treatment groups. Differences in  $\beta$ -diversity were evaluated using the Mann-Whitney  $U$  test. BF, breast-fed; CNTRL, control; FF, formula fed. \*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ . ●, BF + CNTRL; ●, BF + HMO; ●, FF + CNTRL; ●, FF + HMO. PC1, principal component 1; PC2, principal component 2.




**Fig. 4.** Formula supplementation with the human milk oligosaccharide (HMO) 2'-fucosyllactose enhances mesenteric perfusion in experimental necrotising enterocolitis (NEC) via maintenance of intestinal endothelial nitric oxide synthase (eNOS) expression. (a) Representative confocal micrographs of terminal ileal whole mounts from wild-type neonatal mice from the indicated treatment groups: breast-fed controls (BF), breast-fed with HMO (BF + HMO, experimental NEC, formula fed (FF) and FF with HMO (FF + HMO), as well as mice that in addition to the experimental NEC model and HMO treatment also

received the eNOS inhibitors *N*<sup>5</sup>-(1-iminoethyl)-L-ornithine dihydrochloride (L-NIO) (FF + HMO + L-NIO) or diphenylethylideneiodonium chloride (DPI) (FF + HMO + DPI) with their formula. After intra-cardiac injection with the fluorescent tracer tomato lectin, which correlates with intestinal blood flow (green), whole mounts were immunostained for platelet endothelial cell adhesion molecule 1 (PECAM-1) to assess the intestinal microvasculature (red). (b) Graph representing villus perfusion index as described in the Materials and methods section expressed as a percentage. (c) Intestinal *eNOS* mRNA expression by quantitative real-time PCR (qRT-PCR) in the indicated treatment groups relative to the housekeeping gene *RPL0*. (d) SDS-PAGE immunoprecipitation Western blot (IP-WB) performed on the terminal ileum of wild-type mice in the indicated treatment groups. IgG is shown as a loading control (i); densitometry quantification with Image J performed on three samples per group in (ii). \*  $P < 0.05$  v. breast-fed control animals, \*\*  $P < 0.05$  v. FF. Values are means with their standard errors. Scale bar is 50  $\mu$ m. Representative of at least three separate experiments, where each mouse represents an individual symbol on a graph.




**Fig. 5.** The human milk oligosaccharide (HMO), 2'-fucosyllactose failed to protect against necrotising enterocolitis (NEC) in the presence of endothelial nitric oxide synthase inhibition. (a) Representative haematoxylin–eosin micrographs of the terminal ileum of wild-type mice in the indicated treatment groups: breast-fed controls (Ctrl), formula fed (FF), FF plus HMO (FF + HMO) and FF + HMO plus diphenyleiodonium chloride (DPI) (FF + HMO + DPI) or FF + HMO and *N*5-(1-iminoethyl)-L-ornithine dihydrochloride (L-NIO) (FF + HMO + L-NIO). (b) *IL-1β* mRNA expression from the terminal ileum of the

mice in the indicated treatment groups (□, breast-fed mice; ■, FF mice with indicated treatment groups) relative to the housekeeping gene *RPL0*. \*  $P < 0.05$  v. breast-fed control (Ctrl) animals, \*\*  $P < 0.05$  v. FF control (Ctrl), \*\*\*  $P < 0.05$  v. FF + HMO. (c) NEC severity score assessed by a pathologist blinded to the study conditions. \*  $P < 0.05$  v. breast-fed controls, \*\*  $P < 0.05$  v. breast-fed + HMO + DPI, \*\*\*  $P < 0.05$  v. breast-fed + HMO + L-NIO. Values are means with their standard errors. Scale bar is 50  $\mu\text{m}$ . Representative of at least three separate experiments, where each mouse represents an individual symbol on a graph.



**Fig. 6.** The human milk oligosaccharide (HMO) 2'-fucosyllactose does not protect against necrotising enterocolitis (NEC) or enhance intestinal perfusion in endothelial nitric oxide synthase (*eNOS*<sup>-/-</sup>) mice. (a) Representative haematoxylin–eosin micrographs of the terminal ileum of *eNOS*<sup>-/-</sup> mice in the indicated treatment groups. (b) Representative confocal micrographs of terminal ileal whole mounts from *eNOS*<sup>-/-</sup> mice that received HMO and were either breast-fed (BF + HMO) or were formula-fed (FF + HMO). Whole mounts were stained for platelet endothelial cell adhesion molecule 1 (PECAM-1) to assess the microvasculature of the intestine and subjected to intra-cardiac injections with tomato lectin as a marker of intestinal perfusion (green). (c) Graph representing villus perfusion index as described in the Materials and methods section expressed as a percentage. (d) NEC severity score assessed by a pathologist blinded to the study conditions. (e) *IL-1β* mRNA expression from the terminal ileum of the mice in the indicated treatment groups. \*  $P < 0.05$

v. breast-fed control animals, \*\*  $P < 0.05$  v. BF + HMO. Values are means with their standard errors. Scale bar is 50  $\mu\text{m}$ . Representative of at least three separate experiments, where each mouse represents an individual symbol on a graph. qRT-PCR, quantitative real-time PCR.



**Fig. 7.** Expression of endothelial nitric oxide synthase (eNOS) is enhanced by the human milk oligosaccharide (HMO) 2'-fucosyllactose in HUV-EC-C (HUVEC). (a) *eNOS* mRNA by quantitative real-time PCR (qRT-PCR) from HUVEC in the indicated treatment groups: vehicle control (Ctrl), lipopolysaccharide (LPS), HMO alone (HMO) and LPS with HMO (LPS + HMO) relative to the housekeeping gene *RPL0*. (b) Representative confocal micrographs of HUVEC with the indicated treatment groups stained for eNOS (red) and 4,6-diamidino-2-phenylindole, dihydrochloride (DAPI) (blue). \*  $P < 0.05$  v. vehicle control, \*\*  $P < 0.05$  v. LPS. Values are means with their standard errors. Scale bar is 10 μm. Results representative of three separate experiments with over 50 high power fields per group imaged.

**Table 1**

## List of primers

Gene	Species	Forward sequence	Reverse sequence	Amplicon size (bp)
<i>RPL0</i>	Mouse/human	GGCGACCTGGAAGTCCAAC	CCATCAGCACACAGCCTTC	143
<i>IL-6</i>	Mouse	GGCTAAGGACCAAGACCATCAA	TCTGACCACAGTGAGGAATGTCCA	138
<i>TLR4</i>	Mouse	TTTATTTCAGAGCCGTTGGTG	CAGAGGATTGCCTCCCAT	186
<i>IL-1<math>\beta</math></i>	Mouse	AGTGTGGATCCCAAGCAATACCCA	TGTCTGACCACTGTGTTTCCCA	175
<i>iNOS</i>	Mouse	CTGCTGGTGGTGACAAGCACATTT	ATGTCATGAGCAAAGGCGCAGAAC	167
<i>eNOS</i>	Mouse	AGGACATATGTTTGTCTGCGGCGA	AAATGTCCTCGTGGTAGCGTTGCT	155
<i>eNOS</i>	Human	ATGTTTGTCTGCGGCGATGTTACC	TGTCCTCGTGGTAGCGTTGCTGAT	145
<i>eNOS<sup>ko</sup></i>	Mouse	TGGAAGGGAAGTGCAGCAAA	GGCCAGTCTCAGAGCCATAC	151

*RPL0*, ribosomal protein large, P0; *TLR4*, toll-like receptor 4; *iNOS*, inducible nitric oxide synthase; *eNOS*, endothelial nitric oxide synthase.